Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results
Date:5/15/2009

a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

  • For more information about PharmAthene, please visit www.PharmAthene.com.

    Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product cand
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
    4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
    5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
    6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
    7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
    8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
    9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
    10. PharmAthene to Delay Release of Full Year 2007 Financial Results
    11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/6/2015)... Park Systems , world-leader in ... high vacuum AFM system in the market that meets ... manufacturing. Park NX-Hivac is ideal for academic and industrial ... highly doped semiconductor processing where more highly sophisticated failure ... vacuum scanning spreading resistance microscopy (SSRM) of Park NX-Hivac ...
    (Date:5/6/2015)... 06, 2015 Histogen, Inc., a ... products of cells grown under simulated embryonic conditions, ... treatment candidate for melanoma during the 2015 Society ... May 6-9, 2015 in Atlanta, GA. , Histogen ... a soluble material with anti-oncologic properties, with potential ...
    (Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
    (Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
    Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
    ... in Principle Reached to Terminate Marketing Agreement with Triax ... Pyratine-6(TM) on Most Favorable Terms, NAPA, Calif., May ... Sciences company engaged in the development,of technologies that target ... the quarter ended March 31, 2008 and an agreement ...
    ... Highest-risk precancerous condition of esophagus eliminated in 90 percent ... ... 15 BARRX Medical, Inc., the,global technology leader for treating precancerous ... patients in a,multi-center U.S. study were free of the highest-risk of ...
    ... million or 11 cents ... per share ... Inc. (OTC Bulletin Board: CBPO) ("CBP" or the,"Company"), one of the ... reported financial results for,the first quarter ended on March 31, 2008., ...
    Cached Biology Technology:Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3China Biologic Products Reports First Quarter 2008 Results 2China Biologic Products Reports First Quarter 2008 Results 3China Biologic Products Reports First Quarter 2008 Results 4China Biologic Products Reports First Quarter 2008 Results 5China Biologic Products Reports First Quarter 2008 Results 6China Biologic Products Reports First Quarter 2008 Results 7China Biologic Products Reports First Quarter 2008 Results 8China Biologic Products Reports First Quarter 2008 Results 9China Biologic Products Reports First Quarter 2008 Results 10
    (Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
    (Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
    (Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
    Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
    ... From an environmental perspective, Daphnia pulex ... on the planet. Scientists know how this species responds ... important model for ecological and evolutionary research. Its genome, ... and genes interact. Until now. An international team ...
    ... evolutionary past, stress often meant imminent danger, and ... our body,s stress response is to stock-pile blood-clotting ... (MMPU), a collaboration between the European Molecular Biology ... of Heidelberg Medical Centre, have discovered how stressed ...
    ... found in 68 percent of dairy herds and causes ... US dairy industry. A contagious, chronic and usually fatal ... reduces a cow,s milk production, causes weight loss in ... animals., The National Institute for Mathematical and Biological Synthesis ...
    Cached Biology News:Massive Daphnia genome leads to understanding gene-environment interactions 2Massive Daphnia genome leads to understanding gene-environment interactions 3Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3Wasting disease in cattle focus of workshop 2
    ... microarrays containing peptidomimetics built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ... completely customer specified. Thousands of customer ...
    ... OPEP-01009 is a 16 amino acid (amino acids 3-18) synthetic ... The sequence of this peptide is (amino to carboxy ... - V - K - L - R - A ... - K(18). This peptide may be used for ...
    ... is the industry standard microarray image analysis ... imaging and analysis tools, visualizations, automation capabilities, ... is included with every GenePix scanner, and ... scanners and all types of arrays. A ...
    ... Superior Protein Detection and Quantitation Over ... Proteomic Imaging System is a highly sensitive ... life science research applications. ProXPRESS 2D provides ... dyes in the UV and VIS spectrum ...
    Biology Products: